Growth and Expansion of the Pharmaceutical Industry will Emerge as a Determinant for the Global API Intermediates Market

API intermediates are used against a range of chronic and acute diseases such as Alzheimer's diseases. According to the Alzheimer's Association, 5.8 million people in the United States will have Alzheimer's disease by 2020. This disease is the sixth biggest cause of death in the United States, and it is more common in persons over the age of 65. This number is predicted to rise to 14 million by the time the baby-boomer generation reaches 65 years old, aggravating the situation over the projection period. Every 33 seconds, a new case of the disease is projected to emerge by 2050. ​

Access Full Report @ https://www.databridgemarketresearch.com/reports/global-api-intermediates-market

Global API intermediates market is expected to reach USD 37,423.56 million by 2028 from USD 23,705.73 million in 2020, growing with a CAGR of 6.4% in the forecast period of 2021 to 2028. Increasing demand for advanced medical technologies for diagnostic and treatment purposes and the rising healthcare expenditure and government support and the rising number of chronic diseases are some of the drivers boosting the growth of the market. Moreover, extensive research is going on to provide an innovative and highly safe treatment for the API intermediates which will also act as an important determinant. Rising geriatric population base, increasing awareness about the availability of treatment options in the developing economies and rising personal disposable income are some other important market growth determinants.

API Intermediates Market

Rise in the geriatric population base globally is expected to drive the market's growth rate

With the growing geriatric population, chronic and other age-related diseases are also increasing. The elderly population brings a greater chance of health issue, the rapid growth in geriatric population are more prone to various types of disorders. The high prevalence of chronic diseases such as cancer, diabetes, cardiovascular disease, respiratory diseases, and many other diseases, which are now a day's burden to both the market players, physicians and patient population, will act as a vital market growth determinant. Increased expenditure by public and private players on the development of healthcare infrastructure will also promote the market growth rate. Continuous research and development pertaining to the deployment of advanced healthcare technologies will widen the scope of growth.  

Report Scope and Market Segmentation

Report Metric

Details

Forecast Period

2021 to 2028

Base Year

2020

Historic Years

2019 (Customizable to 2013 - 2018)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

Type (Veterinary Drug Intermediates, Pharmaceutical / Bulk Drug Intermediates), Product (Bromo Compound, O-Benzyl Salbutamol, Hemisulfate, Oxirane, Bisoprolol Base, Chiral PCBHP, Pheniramine Base, Chlorpheniramine Base, Brompheniramine Base, Mepyramine/Pyrilamine Base, 6-Amino-1,3-Dimethyl Uracil, Theofylline, Acefylline, Xanthine, Nitriles, Others), Therapeutic Type (Autoimmune Diseases, Oncology, Metabolic Diseases, Ophthalmology, Cardiovascular Diseases, Infectious Diseases, Neurology, Respiratory Disorders, Dermatology, Urology, Others), Customers (Direct Users/Pharma Companies, Traders/Wholesalers/Distributors, Associations/Govt. Institutions/Pvt Institutions), End User (API Manufacturer, Finished Product Manufacturer), Distribution Channel (Direct Tender, Retail Sales, Others)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Market Players Covered

HIKAL Ltd. (India), Cambrex Corporation (U.S.), Ganesh-Group (India), AlzChem Group AG (Germany), Vasudha Pharma (India), Anyang General Chemical Co.,Ltd. (China), Sarex (India), Sandoo Pharmaceuticals and Chemicals Co., Ltd. (India), Atul Ltd (India), Sandoz International GmbH (Germany), Aceto (U.S.), Supriya Lifescience Ltd. (India), LEVACHEM COMPANY LIMITED (Hong Kong), Vertellus (U.K.), Dishman Carbogen Amcis Ltd (India), Sanofi (France), Divi's Laboratories Limited (India), AARTI INDUSTRIES LIMITED (India), Aurobindo Pharma (India) and BASF SE (Germany) among others.             

Data Points Covered in the Report

In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Segment Analysis:

Global API intermediates market is categorized into six notable segments which are based on the type, product, therapeutic type, customers, end user, and distribution channel

  • On the basis of type, global API intermediates market is segmented into veterinary drug intermediates and pharmaceutical / bulk drug intermediates. In 2021, the pharmaceutical / bulk drug intermediates segment is expected to dominate the market with 70.90% market share due to rising demand of APIs for the production of finished goods and the rising prevalence of various diseases that require continued production of drugs.
  • On the basis of product, global API intermediates market is segmented into bromo compound, O-benzyl salbutamol, hemisulfate, oxirane, bisoprolol base, chiral PCBHP, pheniramine base, chlorpheniramine base, brompheniramine base, mepyramine/pyrilamine base, 6-amino-1,3-dimethyl uracil, theofylline, acefylline, xanthine, nitriles, and others. In 2021, nitriles segment is expected to dominate the market with 8.92% market share due to the high cost of the products and continues research and development for the innovative APIs.
  • On the basis of therapeutic type, global API intermediates market is segmented into autoimmune diseases, oncology, metabolic diseases, ophthalmology, cardiovascular diseases, infectious diseases, neurology, respiratory disorders, dermatology, urology, and others. In 2021, cardiovascular diseases segment is expected to dominate the market with 18.40% market share because cardiovascular is the leading cause of death globally. In 2017, according to American College of Cardiology 800,000 deaths occur due to cardiovascular diseases in U.S.
  • On the basis of customers, global API intermediates market is segmented into direct users/pharma companies, traders/wholesalers/distributors, and associations/govt. institutions/pvt institutions. In 2021, the direct users/pharma companies segment is expected to dominate the market with 56.73% market share because APIs manufacture is the intermediates' primary and direct user. Rising Contract manufacturing also boost the market.  
  • On the basis of end users, global API intermediates market is segmented into API manufacturer, and finished product manufacturer. In 2021, API manufacturer segment is expected to dominate the market with 62.71% market share because intermediates are the primary chemical substrate of the APIs, which can be further converted in APIs. So, the intermediates is widely used by the API manufacturer to reduce the cost of manufacturing.
  • On the basis of distribution channel, the global API intermediates market is segmented into direct tender, retail sale, and others. In 2021, direct tender segment is expected to dominate the market with 66.32% market share because direct tender provides huge margin for the purchase good and direct tender has competitive selection of contractor and consultants there is accountability.

Direct tender dominates the distribution channel segment of the API intermediates market

In 2021, direct tender segment will emerge as the dominating segment with 66.3% market share. This is because of the cost of healthcare; healthcare service providers are focusing on better services for customers along with reducing the overall cost. Also, growth and expansion of the direct tender distribution channel will yet again bolster the growth and dominance of this segment.

Major Players

Data Bridge Market Research recognizes the following companies as the major API intermediates market players in advanced wound care market are Atul Ltd (India), HIKAL Ltd. (India), Vasudha Pharma (India), BASF SE (Germany), AARTI INDUSTRIES LIMITED (India), Aurobindo Pharma (India) and Divi's Laboratories Limited.

API Intermediates Market

Market Development – 

  • In January 2021, Vertellus were acquired by the company, Pritzker Private Capital who partners with the middle-market companies established in North America and builds up the long-term relationship with that company. As Vertellus is considered a leading company or provider of specialty chemicals in different sectors such as healthcare, food & agriculture, personal care, transportation, and coatings, PPC has partnered with the company. This helped the company, Vertellus, increase their market growth, which will drive their company's revenues.
  • In August 2020, Dishman Carbogen Amcis Ltd announced that the company will expand their API manufacturing capacity of Switzerland-based CARBOGEN AMCIS to meet the increasing demand form the consumer side. The company has invested USD 110.46 million to enhance their manufacturing capacity. The increase in API manufacturing will directly increase the production and requirement of intermediates which means that the company has to increase the manufacturing of both API and their intermediates. This expansion helped the company enhance their production in both the fields that are APIs and their intermediates, which will increase the company revenue.
  • In November 2020, Cambrex Corporation announced that the company will expand their API manufacturing capacity to meet the increasing demand form the consumer side. The company has invested USD 50 million to enhance their manufacturing capacity. The increase in API manufacturing will directly increase the production and requirement of intermediates which means that the company has to increase the manufacturing of both API and their intermediates. This expansion helped the company enhance its production in both the fields that are APIs and their intermediates, which will increase the company revenues.

Regional Analysis

Geographically, the countries covered in the API intermediates market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

As per Data Bridge Market Research analysis:

North America is the dominant region in API intermediates market during the forecast period 2021 - 2028

North America is dominating the global API intermediates market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. Because of growing healthcare expenditure and well-established healthcare infrastructure for the pharmaceutical/bulk drug intermediates segment, the United States dominates the North American API intermediates market and is predicted to grow at the fastest rate from 2021 to 2028. The U.S is dominating in North American market due to rise in use of medical devices and increasing awareness towards their health. Also, existence of advanced healthcare technologies in this region is another reason for this region's dominance in the global market.   

Asia-Pacific is estimated to be the fastest-growing region in API intermediates market the forecast period 2021 - 2028

Asia-Pacific is expected to grow during the forecast period due to the increasing patient population and rapid development of infrastructural facilities in emerging economies in this region. In addition to this, rising private and public expenditure on the development of healthcare industry infrastructure in the developing and backward economies and increasing per-capita income are expected to propel the market's growth rate in this region. China is expected to dominate the Asia-Pacific region due to the rising investments and the increased funding for the development of manual resuscitators. Also, the increasing geriatric population base, surging incidence rate of chronic and acute disorders and diseases, and rising medical tourism are important market growth determinants.

COVID-19 Impact Analysis

The COVID-19 epidemic had a positive impact on the market in 2020, as governments and big businesses are manufacturing large quantities of ingredients to meet demand for COVID-19 treatment. As a result of the COVID-19 pandemic, medication companies have redirected their models to focus on a bigger group of patients. For example, the United States demanded that India import hydroxychloroquine (HCQ) to treat coronavirus. The virus has also impacted Canada's medicine supply system, potentially causing complications for patients. Canadian pharmaceutical companies are expanding their partnerships with nations other than China to get access to new markets.

For more detailed information about the API intermediates market report, click here – https://www.databridgemarketresearch.com/reports/global-api-intermediates-market